Daré Bioscience to Participate in H.C. Wainwright BIOCONNECT 2022 Conference
January 04, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
December 07, 2021 16:15 ET
|
Daré Bioscience, Inc.
Prescribing information supports positioning of XACIATO as a first line option for the treatment of bacterial vaginosisThis marks the first FDA-approved product in Daré’s portfolio of potential first...
Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update
November 10, 2021 08:00 ET
|
Daré Bioscience, Inc.
Significant progress on several key clinical and corporate initiatives with the portfolio during the third quarter, including DARE-BV1 NDA acceptance and Ovaprene NIH CRADA for the pivotal Phase 3 ...
Daré Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference
November 09, 2021 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
Daré Bioscience to Host Third Quarter 2021 Financial Results and Company Update Conference Call and Webcast on November 10, 2021
November 03, 2021 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Bioscience to Participate in Panel Discussion at DTC Perspectives’ Xpectives.Health Summit, October 12-14, 2021
October 06, 2021 08:51 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced its participation in DTC Perspectives’ Xpectives.Health...
Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1
September 27, 2021 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a Notice of Award of a grant from the Eunice Kennedy Shriver...
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy
September 23, 2021 08:00 ET
|
Daré Bioscience, Inc.
Investigational therapy for women who cannot, or should not, take supplemental estrogen Potential to be the first treatment for vulvar and vaginal atrophy specifically developed for patients with...
Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...